Key Sessions
Mark Farmery
Building an Industrialised Platform for the Development and Manufacture of Next-Generation T Cell Therapies
Anocca
Cristina Martinez Munoz
Manufacturing Excellence in cell therapy
Kite Pharma EU B.V.
keyboard_arrow_right
Search & Filter keyboard_arrow_right
keyboard_arrow_left Hide
Main Conference - Day 2 - GMT (Greenwich Mean Time)
keyboard_arrow_leftSearch & Filter
search
Streams
Main Conference - Day 2 - GMT (Greenwich Mean Time)
search
Streams
08:00 - 08:45
Morning Yoga
08:45 - 09:30
Coffee and Registration
Showing 1 of 1 Streams
Opening Keynote Plenary
09:30 - 09:40
Chairperson's Opening Remarks
- Miguel Forte, MD, Ph.D. - President-Elect, International Society for Cell & Gene Therapy
09:40 - 10:20
Manufacturing Excellence in cell therapy
- Kite, a Gilead Company, the leader in cell therapy
- Manufacturing cell therapies: unique processes and challenges
- Kite’s manufacturing network: delivering cell therapies to eligible patients across Europe and the World
- Building on existing capabilities to meet increasing patient demand
- Delivering innovative therapies in Europe: Barriers to access CAR T-cell therapy
- Next chapter in commercializing cell therapies
- Cristina Martinez Munoz - Senior Director Manufacturing, Kite Pharma EU B.V.
10:20 - 11:00
Morning Coffee and Networking Break in Exhibition & Poster Hall
Showing 3 of 3 Streams
Cell Therapy Manufacturing & Analytics
Gene Therapy Manufacturing & Analytics
CGT Partnering, Commercialization and Supply Chain
11:00 - 11:05
Chairperson's Opening Remarks
- Leopold Bertea - Chief Technology Officer, Mendus AB
11:05 - 11:40
Building an Industrialised Platform for the Development and Manufacture of Next-Generation T Cell Therapies
- Mark Farmery - Chief Development Officer, Anocca
11:40 - 12:15
Large-scale manufacturing of leukemic-derived dendritic cells as a basis for novel cancer immunotherapies
- Leopold Bertea - Chief Technology Officer, Mendus AB
12:15 - 12:45
Considerations for biosafety testing of cell and gene therapies
- Richard Adair - Senior Virology Manager, SGS
11:00 - 11:05
Chairperson's Opening Remarks
- Jun Li - Associate Director, Upstream Process Development, Gene Therapy, Ultragenyx Pharmaceutical
11:05 - 11:40
Learnings from a cell therapy manufacturer on working with a CDMO to develop and establish a manufacturing process
- Terri Gaskell - CTO, Rinri Therapeutics
11:40 - 12:15
Revolutionizing Cell and Gene Therapy: The Impact of Advanced Osmolality Testing on Process Development and Manufacturing
- Kendal Studd - Field Application Specialist, Advanced Instruments
12:15 - 12:45
Streamlining AAV characterization with automated mass photometry
- Perla Vega Dominguez - Technical Sales Specialist, Refeyn
11:00 - 11:05
Chairperson's Opening Remarks
- Dan Stanton - Managing Editor, Bioprocess Insider, Informa Connect
11:05 - 11:40
Managing Durability of CGT: Communicating Value and Reducing Uncertainty
- Ohad Karnieli, Ph.D., MBA - CEO, Adva Biotechnology
- Miguel Forte, MD, Ph.D. - President-Elect, International Society for Cell & Gene Therapy
11:40 - 12:15
Navigating Partnership Challenges in CGT amid Changing Market Conditions
- Eric Halioua - President & Chief Executive Officer, PDC*line Pharma
- Thibault Jonckheere - CEO, Exothera
- George Frodsham - CEO, MediSieve Limited
12:15 - 12:45
How to Optimise Reimbursement Strategies for CGT – Lessons Learned from Payers and Asset Holders
- Brian Gavin - Strategy Director Europe, MAP Patient Access
- Kevin McDonagh - Director & Country Manager, BioMarin Pharmaceuticals Inc.
- Julie Adrian - Co-Founder & CEO, Alverium Health
- Jim McGrath - Director of Commercial Policy, Irish Pharmaceutical Healthcare Association
Showing 2 of 2 Streams
Break
Live Labs
12:45 - 14:15
Lunch in the Exhibition & Poster Hall
13:30 - 13:40
Live Lab: QC requirements and support for biologics manufacturing
13:40 - 13:50
Live Lab: Maximise the efficiency of your cell and gene therapy shipments
Biocair understands the importance of your cell and gene therapy shipments. Join us at booth 508 where we will be demonstrating our packaging and the 24/7 advanced tracking solutions we offer, made especially with cell and gene therapy in mind.
Showing 3 of 3 Streams
Cell Therapy Manufacturing & Analytics
Gene Therapy Manufacturing & Analytics
CGT Partnering, Commercialization and Supply Chain
14:15 - 14:50
ProTcell: Manufacturing Challenges of T Cell Progenitor Based Therapy, A Phase III Strategy
- Pierre Heimendinger - Chief Technical Officer, Smart Immune
14:50 - 15:20
Building Flexible End-to-End Cell Therapy Manufacturing Strategies
- Luca Alberici - General Manager and Site Head, Cell and Gene Centre of Excellence, AGC Biologics
14:15 - 14:50
Next Generation bioreactors for manufacturing cell and gene therapies using Continues Adaptive Muli parameter control and AI to achieve increased quality, predictability and reproducibility.
- Ohad Karnieli, Ph.D., MBA - CEO, Adva Biotechnology
14:50 - 15:20
ATMP Fluid Management and Freeze/Thaw
- Brian Moloney - Director New Products & Innovation, Single Use Support
14:15 - 14:50
Partners with Purpose: Maximising the Value of Relationships within CGT
- Best practices when working with CDMOs & CROs
- Maximising the value of relationships with CDMO/CROs and Therapeutic Developer
- Balancing research uncertainty and resource utilization – managing risks and choosing the right CDMO
- An increasing focus on environmental, social, and governance (ESG) factors by stakeholders and consumers
- Working together towards improved environmental & patient outcomes
- Thibault Jonckheere - CEO, Exothera
- Franck Toussaint - Executive Director & Co-Founder, Bio Supply Management Alliance Europe (BSMA Europe)
- Eric Halioua - President & Chief Executive Officer, PDC*line Pharma
14:50 - 15:20
Please Move to Another Track
Showing 2 of 2 Streams
Break
Poster Sessions
15:20 - 16:00
Afternoon Coffee and Networking Break in Exhibition & Poster Hall
15:25 - 15:55
Poster Session in the Exhibit & Poster Hall
Check out our scientific poster hall and speak with the authors!
Showing 3 of 3 Streams
Cell Therapy Manufacturing & Analytics
Gene Therapy Manufacturing & Analytics
CGT Partnering, Commercialization and Supply Chain
16:00 - 16:35
Novel Analytical Technologies for Cell Therapy Product Characterisation Strategies
- Monica Raimo - Senior R&D Manager, Glycostem Therapeutics
16:35 - 17:10
Case Study: Development of Potency Assays for Cell Therapies
- Mahwish Natalia - Associate Director Cell Therapies, Takeda Oncology
16:00 - 16:35
Breaking Ground: Innovative Analytical Development for QC Assay Release in Decentralized Cell and Gene Therapy Product Manufacturing
- Sagi Nahum - Senior Director – Analytical Sciences and CMC, Cell and Gene Therapy, Orgenesis
16:35 - 17:10
End of Track for Day 2 - Please Move to Another Track
16:00 - 16:35
Supply chain optimization of a CAR-T therapy
- Hans-Peter Scherzer - Customer Success Project Manager, World Courier
16:35 - 17:10
Scaling Up Supply Chain to Meet Industry Objectives and Growth - Issues, Challenges, Opportunities, and Field Experience
- Franck Toussaint - Executive Director & Co-Founder, Bio Supply Management Alliance Europe (BSMA Europe)
17:10 - 19:10
Networking Reception in Exhibition Hall
Get the Latest Event Updates
Sign up to get the latest event updates and information.
Filter
Streams